Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective, randomised study comparing the use of postoperative topi-cal Nepafenac 0.1% to the use of both postoperative and preoperative Nepafenac 0.1%

Next Previous
X
Search
Trial Profile

A prospective, randomised study comparing the use of postoperative topi-cal Nepafenac 0.1% to the use of both postoperative and preoperative Nepafenac 0.1%

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nepafenac (Primary) ; Cefuroxime; Dexamethasone; Ofloxacin; Tobramycin
  • Indications Ocular inflammation
  • Focus Therapeutic Use

    • Most Recent Events

    • 20 Sep 2021 Cefuroxime, Dexamethasone , Ofloxacin, Tobramycin are not in focus but these are adminsterd at end of surgry, so added it. Though source mentions healthy subject, pts undergoing catarct surgey are enrolled, so added patients.
    • 20 Sep 2021 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top